IL6 and breast cancer: Although Compound 182 effectively repressed AT3-OVA mammary tumor growth, this was not accompanied by overt signs of morbidity or systemic inflammation, since spleen weights and splenic T cell and myeloid numbers were unaltered (Supplementary Fig. 10b, c), and serum levels of pro-inflammatory cytokines, including IL-6, IFNγ, and TNF were not significantly increased (Fig. 10a).